Focused On-demand Library for Serine/threonine-protein kinase WNK1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Erythrocyte 65 kDa protein; Kinase deficient protein; Protein kinase lysine-deficient 1; Protein kinase with no lysine 1

Alternative UPACC:

Q9H4A3; A1L4B0; C5HTZ5; C5HTZ6; C5HTZ7; H6WZW3; O15052; P54963; Q4VBX9; Q6IFS5; Q86WL5; Q8N673; Q96CZ6; Q9P1S9


Serine/threonine-protein kinase WNK1, also known as Protein kinase with no lysine 1, plays a pivotal role in regulating blood pressure and ion transport. It is a key component of the WNK1-SPAK/OSR1 kinase cascade, influencing ion influx and contributing to cellular responses to hyperosmotic stress. WNK1's ability to undergo liquid-liquid phase separation allows it to form a membraneless compartment, concentrating with its substrates for enhanced kinase activity.

Therapeutic significance:

WNK1's involvement in diseases such as Pseudohypoaldosteronism 2C and Neuropathy, hereditary sensory and autonomic, 2A, underscores its potential as a therapeutic target. Understanding the role of WNK1 could open doors to potential therapeutic strategies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.